<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-8123</journal-id>
<journal-title><![CDATA[Revista Colombiana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Colomb.Reumatol.]]></abbrev-journal-title>
<issn>0121-8123</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-81232023000200162</article-id>
<article-id pub-id-type="doi">10.1016/j.rcreu.2021.05.016</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saldarriaga Rivera]]></surname>
<given-names><![CDATA[Lina María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marín Giraldo]]></surname>
<given-names><![CDATA[Christian David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Velasco]]></surname>
<given-names><![CDATA[Fabián Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Tecnológica de Pereira Departamento de Medicina Interna Facultad de Ciencias de la Salud]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Tecnológica de Pereira Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario San Jorge  ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Liga Contra el Cáncer  ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>30</volume>
<numero>2</numero>
<fpage>162</fpage>
<lpage>165</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-81232023000200162&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-81232023000200162&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-81232023000200162&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La alopecia areata (AA) es una enfermedad autoinmune que genera pérdida no cicatrizal de cabello con diferentes grados de afectación, incluyendo la pérdida total de los tallos pilosos. A pesar de ser una entidad benigna, tiene un gran impacto en el ámbito emocional y psicosocial de los pacientes. En la actualidad, se dispone de una amplia variedad de tratamientos tanto tópicos como orales. Se presenta el caso de una paciente de 24 años, con alopecia areata recurrente severa, sin respuesta a múltiples tratamientos previamente prescritos, en quien se descartó una causa secundaria y se confirmó diagnóstico histológico con biopsia. Se inició tratamiento con tofacitinib, un inhibidor de la JAK, con una excelente respuesta clínica al mes de iniciado el tratamiento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[A B S T R A C T Alopecia areata (AA) is an autoimmune disease that generates non-scar loss of hair with varying degrees of involvement, including total loss of hair follicles. Despite being a benign entity, it has a great impact on the emotional and psychosocial life of patients. A wide variety of topical and oral treatments are currently available. We present the case of a 24-year-old patient with severe recurrent alopecia areata without response to multiple pre vious treatments, in which a secondary cause was ruled out and the histological diagnosis was confirmed with biopsy. Treatment with tofacitinib, a JAK inhibitor, was started, showing an excellent clinical response after one month of treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Alopecia areata]]></kwd>
<kwd lng="es"><![CDATA[Tofacitinib]]></kwd>
<kwd lng="es"><![CDATA[Janus kinasa]]></kwd>
<kwd lng="en"><![CDATA[Alopecia areata]]></kwd>
<kwd lng="en"><![CDATA[Tofacitinib]]></kwd>
<kwd lng="en"><![CDATA[Janus kinase]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pratt]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[King Jr]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Messenger]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Christiano]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Sundberg]]></surname>
<given-names><![CDATA[JP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alopecia areata]]></article-title>
<source><![CDATA[Nat Rev Dis Primers]]></source>
<year>2017</year>
<numero>3</numero>
<issue>3</issue>
<page-range>17011</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lennard-Jones]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alopecia areata, vitiligo, scleroderma and ulcerative colitis]]></article-title>
<source><![CDATA[Proc R Soc Med]]></source>
<year>1974</year>
<numero>67</numero>
<issue>67</issue>
<page-range>1010-2</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Kadyan]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alopecia areata and autoimmunity: a clinical study]]></article-title>
<source><![CDATA[Indian J Dermatol]]></source>
<year>2008</year>
<numero>53</numero>
<issue>53</issue>
<page-range>70-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Mullangi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Qureshi]]></surname>
<given-names><![CDATA[AA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. Alopecia areata and associated comorbid conditions]]></article-title>
<source><![CDATA[JAMA Dermatol.]]></source>
<year>2013</year>
<numero>149</numero>
<issue>149</issue>
<page-range>789-94</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghanizadeh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ayoobzadehshirazi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of psychiatric disorders comorbidities in patients with alopecia areata.]]></article-title>
<source><![CDATA[Int J Trichology]]></source>
<year>2014</year>
<numero>6</numero>
<issue>6</issue>
<page-range>2-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Craiglow]]></surname>
<given-names><![CDATA[BG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2016</year>
<numero>75</numero>
<issue>75</issue>
<page-range>806</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strazzulla]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[EHC]]></given-names>
</name>
<name>
<surname><![CDATA[Avila]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lo Sicco]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Brinster]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Christiano]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alopecia areata: an appraisal of new treatment approaches and overview of current therapies.]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2018</year>
<numero>78</numero>
<issue>78</issue>
<page-range>15-24</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rencz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gulácsi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Péntek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wikonkál]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Baji]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brodszky]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[lopecia areata and health-related quality of life: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2016</year>
<numero>175</numero>
<issue>175</issue>
<page-range>561-71</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okamoto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ogawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sugiura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shimomura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Aoki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients]]></article-title>
<source><![CDATA[J Autoimmun]]></source>
<year>2004</year>
<numero>23</numero>
<issue>23</issue>
<page-range>257-66</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of antinuclear antibody positivity in patients with pattern hair loss]]></article-title>
<source><![CDATA[Ann Dermatol]]></source>
<year>2015</year>
<numero>27</numero>
<issue>27</issue>
<page-range>210-2</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Messenger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[McKillop]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Farrant]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[McDonagh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sladden]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[British Association of Dermatologists' guidelines for the management of alopecia areata 2012]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2012</year>
<numero>166</numero>
<issue>166</issue>
<page-range>916-26</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Jabbari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cerise]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2014</year>
<numero>20</numero>
<issue>20</issue>
<page-range>1043-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Damsky]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[BA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[JAK inhibitors in dermatology: the promise of a new drug class]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2017</year>
<numero>76</numero>
<issue>76</issue>
<page-range>736-44</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sebaratnam]]></surname>
<given-names><![CDATA[DF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[JAK inhibitors for alopecia areata: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2019</year>
<numero>33</numero>
<issue>33</issue>
<page-range>850-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Craiglow]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[BA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis]]></article-title>
<source><![CDATA[J Invest Dermatol]]></source>
<year>2014</year>
<numero>134</numero>
<issue>134</issue>
<page-range>2988-90</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crispin]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Craiglow]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shankar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Urban]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata]]></article-title>
<source><![CDATA[JCI Insight]]></source>
<year>2016</year>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Craiglow]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[BA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2017</year>
<numero>76</numero>
<issue>76</issue>
<page-range>22-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jabbari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sansaricq]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cerise]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bitterman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ulerio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis]]></article-title>
<source><![CDATA[J Invest Dermatol.]]></source>
<year>2018</year>
<numero>138</numero>
<issue>138</issue>
<page-range>1539-45</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
